
Biophore seeks DCGI nod for Aviptadil use in COVID-19 treatment
The Hindu
Company plans to go for commercial production on receipt of approval
Drugmaker Biophore India Pharmaceuticals on Friday said it has applied to the Drugs Controller General of India (DCGI) seeking emergency use approval for Aviptadil Inhalation in the treatment of moderate to severe COVID-19 patients. The Hyderabad-based company said it has developed the product technology at its research and development facility on the basis of the globally available product. It plans to commence commercial production immediately on receipt of the approval. Aviptadil is a synthetic form of Vasoactive Intestinal Peptide that when administered “results in rapid clinical recovery in patients with severe SARS-COV-2 infection. These observations are based on results of multiple trials of Aviptadil against COVID-19 globally in patients with respiratory failure and the same have been submitted to DCGI for review,” a release from Biophore said.More Related News

The High Court of Karnataka on Tuesday ordered the issue of a notice to the State government on a PIL petition, which had complained about disturbances caused to people residing in the localities around the National Public School situated in Rajajinagar 5th block due to use of loudspeakers with high volume in the school and parking of school buses in residential areas.












